Measurement of Distinct Biological Pools of Hydrogen Sulfide in Women With Cardiovascular Disease

Louisiana State University Health Sciences Center Shreveport

Status: Completed

Conditions: Cardiovascular Disease

Study type: Observational

Funder types: Other

Identifiers

NCT02180074

SRKH2SPOOLS

Details and patient eligibility

About

Cardiovascular disease which includes coronary artery disease and peripheral artery disease remains the leading cause of death among women in the United States. The impact of cardiovascular in women was not recognized by clinicians for a long time. It is now evident that, women suffer the consequences of cardiovascular at rates at least as high as those observed in men but there are still major gaps in our understanding this disease in women. Hydrogen sulfide (H2S), a gaseous mediator plays an important role in the cardiovascular system. Research has demonstrated it's critical role in animal ischemia reperfusion models. Hydrogen sulfide exists in distinct biological pools in blood. Recently, the Kevil lab has pioneered the development of new analytical techniques for accurate measurement of all biological pools of H2S. By measuring these distinct pools of H2S in women with and without cardiovascular disease the investigators hope to further understanding of role of H2S in pathophysiology of cardiovascular disease. This research will help to assess the ability of H2S and its distinct biological pools to potentially be a diagnostic marker or a therapeutic target for cardiovascular disease.

Enrollment: 137 patients

Sex: Female

Ages: 40+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Patients presenting to the cardiac catheterization laboratory for coronary or peripheral angiography.
2. Females,Age>40years

Exclusion criteria

1. Inability to provide informed consent.

2. STelevationmyocardialinfarction.

3. Cardiogenicshock.

4. ABI >1.4 (indicative of non-compressible vessel needing further evaluation to diagnose PAD), unless documented known PAD. 4. Non-atheroscleroticPAD(e.g.Buerger'sdisease). 5. Enrolment in another clinical trial with use of experimental therapeutic agents.

Trial design

137 participants in 5 patient groups

I

Description:

Women without PAD (ABI \>1.0 and \<1.4) or CAD, and \< 2 risk factors for cardiovascular disease (to serve as healthy controls)

II

Description:

Women without PAD (ABI\>1.0 and \<1.4) or CAD and \> 2 risk factors for cardiovascular disease

III

Description:

Women with PAD as defined by ABI \<0.9 and a coronary angiogram without any significant coronary artery disease.

IV

Description:

Women with CAD without PAD, as defined by \>50% stenosis by coronary angiography and ABI \>1.0 and \<1.4.

V

Description:

Women with both CAD and PAD.